Login
$FTH
$9.23 -$0.05 (0.54%) After hours

$FTH 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Other Events

FAETH THERAPEUTICS PIKTOR Phase 2 Endometrial Cancer Topline Results NOVEMBER 9, 2026 Exhibit 99.1

09 Nov 2026 8-K: Regulation FD Disclosure

Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

03 Nov 2026 8-K: Results of Operations and Financial Condition

Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end

27 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

17 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

04 Aug 2026 8-K: Results of Operations and Financial Condition

— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end —

23 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 21, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), approved one-time supplemental grants ...

18 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

On June 18, 2026, Faeth Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM S...

15 Jun 2026 8-K: Termination of a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +3 more

Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer

10 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

(a) Successor to Prior Plan. The Plan is the successor to the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; and (ii) all outstanding awards granted under the Prior Plan will remain su...

22 May 2026 8-K: Other Events

On May 22, 2026, Sensei Biotherapeutics, Inc. (the “Company”) announced an update regarding the expected reconstitution of the board of directors of the Company (the “Board”) in connection with the Company’s 2026 Annual Meeting of Stockh...

21 May 2026 8-K: Other Events

On February 17, 2026, Sensei Biotherapeutics, Inc. (the “Company”) acquired Faeth Holdings Therapeutics, Inc. (“Faeth HoldCo”) and its wholly owned subsidiary Faeth Therapeutics, LLC (“Faeth Subsidiary” and, together with Faeth HoldCo, “...

15 May 2026 8-K: Results of Operations and Financial Condition

First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer

16 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

30 Mar 2026 8-K: Results of Operations and Financial Condition

Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway

18 Feb 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more

Form of Certificate of Designation of Series B Convertible Preferred Stock

13 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

23 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 Nov 2025 8-K: Results of Operations and Financial Condition

BOSTON, MA – November 14, 2025 – Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial r...

30 Oct 2025 8-K: Regulation FD Disclosure

BOSTON, October 30, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support